Teva Pharmaceutical Industries (NYSE:TEVA) had its target price reduced by equities researchers at Deutsche Bank from $20.00 to $18.00 in a note issued to investors on Friday. The brokerage currently has a “hold” rating on the stock. Deutsche Bank’s price target suggests a potential downside of 3.59% from the stock’s current price.
A number of other analysts also recently weighed in on TEVA. BTIG Research downgraded Teva Pharmaceutical Industries from a “neutral” rating to a “sell” rating and set a $17.00 price objective for the company. in a report on Friday, February 2nd. Oppenheimer restated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday, February 8th. Piper Jaffray Companies downgraded Teva Pharmaceutical Industries from a “neutral” rating to an “underweight” rating and set a $11.00 price objective for the company. in a report on Friday. Cantor Fitzgerald set a $18.00 price objective on Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Wednesday, January 3rd. Finally, Maxim Group restated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday, February 8th. Ten investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and seven have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $21.26.
Shares of Teva Pharmaceutical Industries (TEVA) traded down $0.60 on Friday, hitting $18.67. The stock had a trading volume of 7,388,306 shares, compared to its average volume of 19,611,525. Teva Pharmaceutical Industries has a one year low of $10.85 and a one year high of $37.94. The company has a market cap of $18,907.76, a PE ratio of -1.15, a price-to-earnings-growth ratio of 1.37 and a beta of 0.60. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20.
Institutional investors have recently modified their holdings of the business. Calton & Associates Inc. acquired a new stake in Teva Pharmaceutical Industries during the 4th quarter worth about $108,000. Bank of Nova Scotia boosted its position in shares of Teva Pharmaceutical Industries by 8.3% during the 2nd quarter. Bank of Nova Scotia now owns 6,903 shares of the company’s stock worth $229,000 after purchasing an additional 528 shares in the last quarter. Penserra Capital Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth about $129,000. Americafirst Capital Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter worth about $303,000. Finally, Fieldpoint Private Securities LLC bought a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth about $171,000. Hedge funds and other institutional investors own 51.93% of the company’s stock.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.